Porcine Vaccines Market by Indication (Arthritis, Diarrhea, Porcine Circovirus Associated Disease), Technology (Conjugate Vaccines, DNA Vaccines, Inactivated Vaccines), End User - Global Forecast 2024-2030

Porcine Vaccines Market by Indication (Arthritis, Diarrhea, Porcine Circovirus Associated Disease), Technology (Conjugate Vaccines, DNA Vaccines, Inactivated Vaccines), End User - Global Forecast 2024-2030

The Porcine Vaccines Market size was estimated at USD 1.71 billion in 2023 and expected to reach USD 1.82 billion in 2024, at a CAGR 6.72% to reach USD 2.70 billion by 2030.

Porcine vaccines are immunological preparations designed to prevent various swine diseases in pigs. These vaccines are created to stimulate the porcine immune system, enabling it to develop defenses against pathogens such as viruses or bacteria that can cause illness. By mimicking the infection, they prepare the swine’s body to recognize and combat the actual pathogens should they be encountered in the future. The rise in the incidence of swine diseases and the growing global consumption of pork products are major driving factors behind the need for porcine vaccines. Furthermore, supportive government initiatives, including subsidies and awareness programs, have encouraged the use of vaccines. However, the need for a cold chain infrastructure creates logistical challenges, particularly in developing countries. Furthermore, the variability in the immune response of different pig breeds can impact vaccine effectiveness and create hurdles for the development and adoption of porcine vaccines. However, key players are exploring novel technologies such as nanotechnology, gene editing strategies, and precision medicine to ensure the development of customized vaccines that can overcome the performance challenges of porcine vaccines. Moreover, investigating new adjuvants to enhance immune response without compromising safety and developing needle-free administration could improve vaccine uptake and reduce stress on animals.

Regional Insights

In the Americas region, particularly the U.S. and Canada, the porcine vaccine market is well-established due to the extensive pig farming industry and a strong emphasis on animal health management. The country sees a significant consumer need for vaccinations against prevalent diseases such as porcine reproductive and respiratory syndrome (PRRS), swine influenza, and others. Producers often adopt the latest vaccines, and purchasing behavior indicates a readiness to invest in advanced solutions for swine herds. Recent research in the U.S. has focused on developing vaccines with improved efficacy and longer immunity periods. Investments in biotechnology companies and government initiatives such as the Veterinary Biologics Program under the United States Department of Agriculture(USDA)-Animal & Plant Health Inspection Service(APHIS) reflect ongoing efforts to strengthen the sector. The EMEA countries represent a diverse market with stringent animal welfare and health regulations. The European consumer requires vaccines that comply with high safety standards, leading to a demand for quality-assured vaccines. The EU’s Horizon 2020 program has seen substantial investments in research addressing swine diseases, which propels the development of new and efficient vaccines. In the APAC region, China represents a highly evolved market for pig meat, thereby accentuating the need for porcine markets. India, with an emerging pig farming industry in the APAC region, presents a moderate but growing demand for porcine vaccines. Consumer needs revolve around affordable and accessible vaccines due to cost-sensitive purchasing behaviors. The government has been encouraging the growth of the swine industry through initiatives that provide support for vaccinations and animal health programs.

Market Insights

• Market Dynamics
  
  The market dynamics represent an ever-changing landscape of the Porcine Vaccines Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
  • Market Drivers
    • Rise in Prevalence of Swine Diseases Worldwide
    • Increasing Demand for High-Quality Pork Meat
    • Government Initiatives to Support Animal Health
    • Market Restraints
      • High Cost of Porcine Vaccine Development and Complex Storage Issues
      • Market Opportunities
        • Technological Advancements in Porcine Vaccine
        • Favorable Investment Landscape For Production of Novel Porcine Vaccines
        • Market Challenges
          • Limited Availability and Awareness Along with Side Effects Associated with Porcine Vaccines
          • Market Segmentation Analysis
            • Technology: Growing innovations in recombinant vaccines due to advancements in genetic engineering and molecular biology technologies
            • End User: Growing need for mass vaccination programs in the hog/pig production farm
            • Market Disruption Analysis
            • Porter’s Five Forces Analysis
            • Value Chain & Critical Path Analysis
            • Pricing Analysis
            • Technology Analysis
            • Patent Analysis
            • Trade Analysis
            • Regulatory Framework Analysis
            FPNV Positioning Matrix
            
            The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Porcine Vaccines Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
            
            Market Share Analysis
            
            The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Porcine Vaccines Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
            
            Recent Developments
            • Zoetis Launches Circomax In The UK
              
              Zoetis has introduced CircoMax to the UK market, a vaccine designed to combat porcine circovirus type 2 (PCV2). This vaccine is formulated to target multiple strains of the virus, offering protection against genotypes PCV2a, PCV2b, and PCV2d. These genotypes represent the primary variants found within the UK’s pig population. The relevance of CircoMax is cemented by current research indicating a shift in the dominant genotypes over time, from PCV2a originally to PCV2b, and most recently to PCV2d, highlighting the dynamic nature of the virus.
              
              Merck Animal Health Launches 3-In-One Swine Vaccine
              
              Merck Animal Health announced the launch of Circumvent CML, a novel trivalent swine vaccine designed to combat key porcine diseases. Circumvent CML marks a significant advancement in swine health, delivering protection against porcine circovirus Type 2a (PCV-2a), porcine circovirus type 2d (PCV-2d), mycoplasma hyopneumoniae, and lawsonia intracellularis in one comprehensive formulation. This innovative vaccine encapsulates the effectiveness of Merck's established antigens and adjuvant systems, previously demonstrated in products such as Circumvent PCV-M G2 and Porcilis Ileitis, providing an integrated solution for swine producers.
              
              Elanco is Exclusive U.S. Distributor of Aptimmune’s PRRS Killed Autogenous Vaccine
              
              Elanco Animal Health Incorporated has secured an exclusive distribution agreement with Aptimmune Biologics, Inc. This arrangement positions Elanco as the sole provider of a novel porcine reproductive and respiratory syndrome (PRRS) vaccine, leveraging Aptimmune's innovative Barricade formula. This inactivated vaccine would complement Elanco's existing Prevacent PRRS live vaccine, thereby enhancing their portfolio of respiratory illness interventions.
            Strategy Analysis & Recommendation
            
            The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Porcine Vaccines Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
            
            Key Company Profiles
            
            The report delves into recent significant developments in the Porcine Vaccines Market, highlighting leading vendors and their innovative profiles. These include Aptimmune Biologics, Inc., Arko Laboratories, AVAC Vietnam Joint Stock Company, Bayer AG, Bimeda Holdings PLC, Biogénesis Bagó S.A., Boehringer Ingelheim International GmbH, Ceva Sante Animale, Eli Lilly and Company, Endovac Animal Health, FATRO S.p.A., Formosa Biomedical Inc., Genvax Technologies, Inc., HIPRA, S.A., Indian Immunologicals Ltd., KM Biologics Co., Ltd., Kyoto Biken Laboratories, Inc., Malaysian Vaccines & Pharmaceuticals Sdn Bhd., Medgene Labs, Merck & Co., Inc., Nisseiken Co., Ltd., PBS Animal Health, Phibro Animal Health Corporation, Virbac SA, Yenher Agro-Products Sdn. Bhd., and Zoetis Inc..
            
            Market Segmentation & Coverage
            
            This research report categorizes the Porcine Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:
            • Indication
              • Arthritis
              • Diarrhea
              • Porcine Circovirus Associated Disease
              • Porcine Reproductive & Respiratory Syndrome
              • Swine Influenza
              • Technology
                • Conjugate Vaccines
                • DNA Vaccines
                • Inactivated Vaccines
                • Live attenuated Vaccines
                • Recombinant Vaccines
                • Toxoid Vaccines
                • End User
                  • Hog/Pig Production Farm
                  • Veterinary Clinics/Hospitals
                  • Region
                    • Americas
                      • Argentina
                      • Brazil
                      • Canada
                      • Mexico
                      • United States
                        • California
                        • Florida
                        • Illinois
                        • New York
                        • Ohio
                        • Pennsylvania
                        • Texas
                        • Asia-Pacific
                          • Australia
                          • China
                          • India
                          • Indonesia
                          • Japan
                          • Malaysia
                          • Philippines
                          • Singapore
                          • South Korea
                          • Taiwan
                          • Thailand
                          • Vietnam
                          • Europe, Middle East & Africa
                            • Denmark
                            • Egypt
                            • Finland
                            • France
                            • Germany
                            • Israel
                            • Italy
                            • Netherlands
                            • Nigeria
                            • Norway
                            • Poland
                            • Qatar
                            • Russia
                            • Saudi Arabia
                            • South Africa
                            • Spain
                            • Sweden
                            • Switzerland
                            • Turkey
                            • United Arab Emirates
                            • United Kingdom
                            
                            
                            Please Note: PDF & Excel + Online Access - 1 Year

Show more